ARNA

Arena Pharmaceuticals, Inc. Press Releases

$4.01
*  
0.03
0.74%
Get ARNA Alerts
*Delayed - data as of Oct. 17, 2014  -  Find a broker to begin trading ARNA now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
Eisai and Arena Pharmaceuticals Announce Presentation of Lorcaserin HCl Data at the American College of Clinical Pharmacy Annual Meeting
10/13/2014 8:00:00 AM - PR Newswire
▲10.16 % Price Change since this news event. The Volume Ratio is 1.75.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Eisai and Arena Pharmaceuticals Announce Publication of Pooled Phase 3 Clinical Trial Analysis of BELVIQ® (lorcaserin HCl) CIV in Postgraduate Medicine
10/10/2014 11:36:00 AM - PR Newswire
▲8.09 % Price Change since this news event. The Volume Ratio is 2.08.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9/22/2014 8:00:00 AM - PR Newswire


Lorcaserin HCl Data to be Presented at the American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium
9/10/2014 8:00:00 AM - PR Newswire


Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension
9/2/2014 8:00:00 AM - PR Newswire


Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results
8/1/2014 4:30:00 AM - PR Newswire


Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity
7/30/2014 8:00:00 AM - PR Newswire


Eisai and Arena Pharmaceuticals Announce BELVIQ® (lorcaserin HCl) CIV Nominated a Second Time for the Prix Galien Award in the Best Pharmaceutical Agent Category
7/29/2014 8:00:00 AM - PR Newswire


Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1
7/25/2014 8:00:00 AM - PR Newswire